Emergent BioSolutions Inc. 2008 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Reporting Period: Fiscal year ended December 31, 2008
Business Overview: Emergent is a biopharmaceutical company focused on vaccines and immune-related therapeutics for biodefense (bioterrorism) and commercial infectious diseases. The company operates in two segments: Biodefense and Commercial. Its primary revenue driver is BioThrax, the only FDA-approved anthrax vaccine, sold almost exclusively to the U.S. government (HHS and DoD). The company maintains a pipeline of candidates including an rPA anthrax vaccine, anthrax immune globulin, and vaccines for typhoid, tuberculosis, and hepatitis B.
Key Financial Metrics (Year Ended Dec 31, 2008)
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenues | $178.6 million | $182.9 million |
| Product Sales (BioThrax) | $169.1 million | $169.8 million |
| Contracts & Grants | $9.4 million | $13.1 million |
| Net Income | $20.7 million | $22.9 million |
| Diluted EPS | $0.68 | $0.77 |
| Cash & Equivalents | $91.5 million | $105.7 million |
| Total Debt (Principal) | $57.2 million | $57.9 million |
| Working Capital | $98.7 million | $88.6 million |
Margins: Gross margin on product sales was approximately 80% ($169.1M revenue vs. $34.1M cost of sales). Operating margin was approximately 16.8%.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2.4% to $178.6 million. Product sales remained flat in dollar terms but decreased 16% in volume (doses delivered), offset by an 18% increase in average price per dose due to the expiration of a discount on limited shelf-life doses in 2007.
- Contract Revenue Drop: Contracts and grants revenue fell 28% to $9.4 million. This was driven by the absence of an $8.8 million milestone payment from HHS received in 2007 for BioThrax post-exposure development. This was partially offset by $4.4 million recognized from the termination of the Sanofi Pasteur collaboration and $1.8 million from the sale of Pertussis technology to Pfizer.
- R&D Increase: Research and development expenses rose 10% to $59.5 million, reflecting increased spending on biodefense candidates (rPA vaccine, advanced anthrax) and commercial candidates (Typhella Phase IIb).
- Legal Settlement: The company recovered approximately $2.1 million in previously expensed legal fees from the DoD and its insurer, reducing SG&A expenses.
Guidance, Outlook, and Risks
Outlook & Strategy:
- BioThrax Expansion: Management is pursuing label expansions for BioThrax, including a reduced dosing schedule (3 doses vs. 5), extended expiry dating (4 years vs. 3), and post-exposure prophylaxis approval. FDA approval for the 4-year expiry is anticipated in 2009, which could trigger a $34 million price adjustment on existing contracts.
- rPA Vaccine: The company is negotiating a potential $400M-$600M development and procurement contract with BARDA for its recombinant protective antigen (rPA) anthrax vaccine. An award is expected by the end of the first half of 2009.
- Manufacturing: A new 50,000 sq. ft. facility in Lansing, Michigan, is nearing qualification. It is intended for rPA production but may also support BioThrax.
Key Risks & Contingencies:
- Government Dependence: 96% of 2008 revenue came from HHS. Future revenue is heavily dependent on U.S. government appropriations and contract renewals.
- Protein Sciences Litigation: Emergent is in active litigation with Protein Sciences Corporation (PSC) regarding a failed acquisition and a $10 million loan. Emergent is seeking full repayment and damages; PSC has threatened counterclaims.
- Manufacturing Constraints: The company relies on a single contract filler (Hollister-Stier) for BioThrax vials. Qualification of a backup filler is pending FDA approval.
- Regulatory Uncertainty: Approval of new indications (post-exposure) and candidates (rPA) relies on the FDA "animal rule," which carries inherent uncertainty.
Investor Verification Checklist
- Contract Status: Verify the status of the BARDA rPA vaccine contract negotiations and the likelihood of the $400M+ award.
- Regulatory Milestones: Monitor FDA decisions on the BioThrax 4-year expiry dating supplement and the post-exposure prophylaxis BLA supplement.
- Legal Exposure: Track the resolution of the Protein Sciences Corporation litigation and the potential impact of the $10 million note receivable.
- Manufacturing Capacity: Confirm the timeline for FDA qualification of the new Lansing facility and the backup contract filler for BioThrax.
- Debt Covenants: Review compliance with debt covenants, specifically the debt coverage ratio and tangible net worth requirements under the HSBC and Fifth Third Bank agreements.